255 related articles for article (PubMed ID: 29579286)
1. Involvement of Heparanase in the Pathogenesis of Mesothelioma: Basic Aspects and Clinical Applications.
Barash U; Lapidot M; Zohar Y; Loomis C; Moreira A; Feld S; Goparaju C; Yang H; Hammond E; Zhang G; Li JP; Ilan N; Nagler A; Pass HI; Vlodavsky I
J Natl Cancer Inst; 2018 Oct; 110(10):1102-1114. PubMed ID: 29579286
[TBL] [Abstract][Full Text] [Related]
2. Heparanase inhibitors restrain mesothelioma.
Lapidot M; Barash U; Vlodavsky I; Pass H
Oncotarget; 2018 Dec; 9(96):36830-36832. PubMed ID: 30627323
[TBL] [Abstract][Full Text] [Related]
3. Heparanase and basic fibroblast growth factor are co-expressed in malignant mesothelioma.
Davidson B; Vintman L; Zcharia E; Bedrossian C; Berner A; Nielsen S; Ilan N; Vlodavsky I; Reich R
Clin Exp Metastasis; 2004; 21(5):469-76. PubMed ID: 15672872
[TBL] [Abstract][Full Text] [Related]
4. Heparanase gene silencing, tumor invasiveness, angiogenesis, and metastasis.
Edovitsky E; Elkin M; Zcharia E; Peretz T; Vlodavsky I
J Natl Cancer Inst; 2004 Aug; 96(16):1219-30. PubMed ID: 15316057
[TBL] [Abstract][Full Text] [Related]
5. PG545, a heparan sulfate mimetic, reduces heparanase expression in vivo, blocks spontaneous metastases and enhances overall survival in the 4T1 breast carcinoma model.
Hammond E; Brandt R; Dredge K
PLoS One; 2012; 7(12):e52175. PubMed ID: 23300607
[TBL] [Abstract][Full Text] [Related]
6. Heparanase: From basic research to therapeutic applications in cancer and inflammation.
Vlodavsky I; Singh P; Boyango I; Gutter-Kapon L; Elkin M; Sanderson RD; Ilan N
Drug Resist Updat; 2016 Nov; 29():54-75. PubMed ID: 27912844
[TBL] [Abstract][Full Text] [Related]
7. The heparanase inhibitor PG545 is a potent anti-lymphoma drug: Mode of action.
Weissmann M; Bhattacharya U; Feld S; Hammond E; Ilan N; Vlodavsky I
Matrix Biol; 2019 Apr; 77():58-72. PubMed ID: 30096360
[TBL] [Abstract][Full Text] [Related]
8. Heparan sulfate chains contribute to the anticoagulant milieu in malignant pleural effusion.
Hardak E; Peled E; Crispel Y; Ghanem S; Attias J; Asayag K; Kogan I; Nadir Y
Thorax; 2020 Feb; 75(2):143-152. PubMed ID: 31892546
[TBL] [Abstract][Full Text] [Related]
9. Mechanisms of heparanase inhibitors in cancer therapy.
Heyman B; Yang Y
Exp Hematol; 2016 Nov; 44(11):1002-1012. PubMed ID: 27576132
[TBL] [Abstract][Full Text] [Related]
10. A novel translational approach for human malignant pleural mesothelioma: heparanase-assisted dual virotherapy.
Watanabe Y; Kojima T; Kagawa S; Uno F; Hashimoto Y; Kyo S; Mizuguchi H; Tanaka N; Kawamura H; Ichimaru D; Urata Y; Fujiwara T
Oncogene; 2010 Feb; 29(8):1145-54. PubMed ID: 19935710
[TBL] [Abstract][Full Text] [Related]
11. Regulation, function and clinical significance of heparanase in cancer metastasis and angiogenesis.
Ilan N; Elkin M; Vlodavsky I
Int J Biochem Cell Biol; 2006; 38(12):2018-39. PubMed ID: 16901744
[TBL] [Abstract][Full Text] [Related]
12. Tumoral CD10 expression correlates with aggressive histology and prognosis in patients with malignant pleural mesothelioma.
Kadota K; Villena-Vargas J; Nitadori J; Sima CS; Jones DR; Travis WD; Adusumilli PS
Ann Surg Oncol; 2015 Sep; 22(9):3136-43. PubMed ID: 25608772
[TBL] [Abstract][Full Text] [Related]
13. Involvement of heparanase in the pathogenesis of acute kidney injury: nephroprotective effect of PG545.
Abassi Z; Hamoud S; Hassan A; Khamaysi I; Nativ O; Heyman SN; Muhammad RS; Ilan N; Singh P; Hammond E; Zaza G; Lupo A; Onisto M; Bellin G; Masola V; Vlodavsky I; Gambaro G
Oncotarget; 2017 May; 8(21):34191-34204. PubMed ID: 28388547
[TBL] [Abstract][Full Text] [Related]
14. Heparanase regulation of cancer, autophagy and inflammation: new mechanisms and targets for therapy.
Sanderson RD; Elkin M; Rapraeger AC; Ilan N; Vlodavsky I
FEBS J; 2017 Jan; 284(1):42-55. PubMed ID: 27758044
[TBL] [Abstract][Full Text] [Related]
15. PG545, a dual heparanase and angiogenesis inhibitor, induces potent anti-tumour and anti-metastatic efficacy in preclinical models.
Dredge K; Hammond E; Handley P; Gonda TJ; Smith MT; Vincent C; Brandt R; Ferro V; Bytheway I
Br J Cancer; 2011 Feb; 104(4):635-42. PubMed ID: 21285983
[TBL] [Abstract][Full Text] [Related]
16. Dendrimer Heparan Sulfate Glycomimetics: Potent Heparanase Inhibitors for Anticancer Therapy.
Zubkova OV; Ahmed YA; Guimond SE; Noble SL; Miller JH; Alfred Smith RA; Nurcombe V; Tyler PC; Weissmann M; Vlodavsky I; Turnbull JE
ACS Chem Biol; 2018 Dec; 13(12):3236-3242. PubMed ID: 30480427
[TBL] [Abstract][Full Text] [Related]
17. Prognostic significance of soluble mesothelin in malignant pleural mesothelioma: a meta-analysis.
Tian L; Zeng R; Wang X; Shen C; Lai Y; Wang M; Che G
Oncotarget; 2017 Jul; 8(28):46425-46435. PubMed ID: 28507279
[TBL] [Abstract][Full Text] [Related]
18. Proteome screening of pleural effusions identifies galectin 1 as a diagnostic biomarker and highlights several prognostic biomarkers for malignant mesothelioma.
Mundt F; Johansson HJ; Forshed J; Arslan S; Metintas M; Dobra K; Lehtiö J; Hjerpe A
Mol Cell Proteomics; 2014 Mar; 13(3):701-15. PubMed ID: 24361865
[TBL] [Abstract][Full Text] [Related]
19. The Heparanase Inhibitor PG545 Attenuates Colon Cancer Initiation and Growth, Associating with Increased p21 Expression.
Singh P; Blatt A; Feld S; Zohar Y; Saadi E; Barki-Harrington L; Hammond E; Ilan N; Vlodavsky I; Chowers Y; Half E
Neoplasia; 2017 Mar; 19(3):175-184. PubMed ID: 28147305
[TBL] [Abstract][Full Text] [Related]
20. Immunohistochemical Expression of Aquaporin-1 in Fluoro-Edenite-Induced Malignant Mesothelioma: A Preliminary Report.
Angelico G; Caltabiano R; Loreto C; Ieni A; Tuccari G; Ledda C; Rapisarda V
Int J Mol Sci; 2018 Feb; 19(3):. PubMed ID: 29495596
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
